Publication at Faculty of Medicine in Hradec Králové |
2010
Abstract
Cancer patients with thrombosis and haemorrhagy are a particular problem. They have an increased risk of deep vein thrombosis and pulmonary embolism, and they´re more prone to bleeding from anticoagulant therapy.
So it really is a dilemma. Clinical reserch has shown that prevention and initial therapy can consist of subcutaneous low-molecular-weight heparin for an initial period, followed by long-term anticoagulant therapy.